CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...